GPD2 and neoplasm: Metformin monotherapy is also correlated with mitochondrial glycerol-3-phosphate dehydrogenase (MGPDH) downregulation and OXPHOS inhibition in tumor cells characterized by high MGPDH expression are more sensitive to metformin (51).